The Patent Finder

Terms ending in 2036

Kymab Limited

Every in-force patent on Kymab Limited's record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,567,399Antibodies and Immunocytokines
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 9,617,338Antibodies and Immunocytokines
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 9,957,323Anti-Icos Antibodies
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 10,604,576Antibodies and Immunocytokines
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 11,858,996Anti-Icos Antibodies
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 11,965,026ANTI-PD-L1 and IL-2 Cytokines
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 11,920,128Methods, Cells & Organisms
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited